Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Stock Slips 5.21 Percent on Q2 Earnings

NEW YORK, Aug. 9 (GenomeWeb News) - Shares in Sequenom were down 5.21 percent, or $.05, at $.91 in mid-afternoon trading after the company yesterday reported a slight increase in second-quarter revenues as losses slid sharply on lower costs.

 

As GenomeWeb News reported last night, Sequenom posted a rise in second-quarter revenues to $6.2 million, versus $6 million in the year-ago quarter, an increase the company attributed to both the addition of new customers and the upgrading of the firm's analysis systems by existing customers.

 

Sequenom's research and development spending dropped to about $3 million in the quarter from $5.7 million a year earlier.

 

The company posted a net loss of $6 million, or $.15 per share, versus a year-ago loss of $9.8 million, or $.25 per share.

As of June 30, Sequenom had cash, cash equivalents, short-term investments, and restricted cash totaling $25.4 million.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.